Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000421091 | SCV000232262 | uncertain significance | not provided | 2014-10-27 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000421091 | SCV000511414 | uncertain significance | not provided | 2016-09-29 | criteria provided, single submitter | clinical testing | Converted during submission to Uncertain significance. |
Labcorp Genetics |
RCV001051109 | SCV001215243 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-09-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 198560). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. This variant is present in population databases (rs748787013, gnomAD 0.006%). This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 346 of the CNTNAP2 protein (p.Asn346Ser). |